Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This open-label field trial evaluates the effects of treatment with a multi-pathway dietary supplement (Stem Cell 100+) that has been commercially available for several years. The objective of the intervention trial is to determine if normal subjects over 35 years of age experience any observable health benefits from the dietary supplement as to their blood pressure, pulse rate, blood cholesterol, lung capacity, stress levels, or self reported changes in markers of overall health and life expectancy.
Currently, only dietary restriction has been verified to slow the rate of aging and to promote general health. This trial is designed to see whether a complex supplement (Stem Cell 100+) that targets multiple longevity pathways could also have positive effects on several markers of successful aging and good health. Multipath causes of aging include: stem cell function, telomere loss, chronic stress, inflammation, insulin-like growth factors, autophagy, vascular loss, neural dysfunction, and oxidative stress. The goal of the study was to test the effects of this novel multipath intervention strategy in a clinical trial of healthy people using health markers such as blood pressure, cholesterol status, lung function, stress levels, and self-reported health status. Hundreds of published animal and human clinical studies have been done with each of the individual active ingredients in the formulation, which target many critical causes of aging.
Based on their published animal studies showing extension of life span in a model animal and their laboratory work on adult human stem cells, the investigators believe that Stem Cell 100+ will provide evidence of efficacy in addressing multiple index markers of health and life expectancy outcomes.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Stem Cell 100+ Intervention | Experimental | Subjects take one 650 mg capsule by mouth twice daily for an average of 15 weeks |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Stem Cell 100+ | Dietary Supplement | Open-Label 10-Component Dietary Supplement |
|
| Measure | Description | Time Frame |
|---|---|---|
| Blood Pressure | Change in Systolic and Diastolic Blood Pressure | Baseline and at an average of 15 weeks |
| HDL Cholesterol | Change in HDL Cholesterol | Baseline and at an average of 15 weeks |
| Lung Capacity | Change in Peak Expiatory Flow | Baseline and at an average of 15 weeks |
| Stress Level | Change in Heart Rate Variability | Baseline and at an average of 15 weeks |
| Heart Rate | Change in Heart Rate | Baseline and at an average of 15 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Overall Health | Self-Reported Change based on a 7 point range from Much Better (+3) to Much Worse (-3) | From baseline through study completion, an average of 15 weeks |
| Ability to Concentrate or Focus |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Bryant Villeponteau, Ph.D. | Centagen, Inc. | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Accelagen, Inc. | San Diego | California | 92121 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 25879540 | Background | Villeponteau B, Matsagas K, Nobles AC, Rizza C, Horwitz M, Benford G, Mockett RJ. Herbal supplement extends life span under some environmental conditions and boosts stress resistance. PLoS One. 2015 Apr 16;10(4):e0119068. doi: 10.1371/journal.pone.0119068. eCollection 2015. | |
| 11113618 | Background | Villeponteau B, Cockrell R, Feng J. Nutraceutical interventions may delay aging and the age-related diseases. Exp Gerontol. 2000 Dec;35(9-10):1405-17. doi: 10.1016/s0531-5565(00)00182-0. |
| Label | URL |
|---|---|
| Wikipedia description of Villeponteau's contributions to science and medicine | View source |
Not provided
Not provided
| ID | Term |
|---|---|
| D012131 | Respiratory Insufficiency |
| D007593 | Joint Instability |
| D007153 | Immunologic Deficiency Syndromes |
| ID | Term |
|---|---|
| D012120 | Respiration Disorders |
| D012140 | Respiratory Tract Diseases |
| D007592 | Joint Diseases |
| D009140 | Musculoskeletal Diseases |
Not provided
Not provided
Open-label field trial without a placebo.
Not provided
Not provided
Not provided
Not provided
Self-Reported Change based on a 7 point range from Much Better (+3) to Much Worse (-3)
| From baseline through study completion, an average of 15 weeks |
| Joint Flexibility | Self-Reported Change based on a 7 point range from Much Better (+3) to Much Worse (-3) | From baseline through study completion, an average of 15 weeks |
| Work Productivity | Self-Reported Change based on a 7 point range from Much Better (+3) to Much Worse (-3) | From baseline through study completion, an average of 15 weeks |
| Ability to Relax | Self-Reported Change based on a 7 point range from Much Better (+3) to Much Worse (-3) | From baseline through study completion, an average of 15 weeks |
| Cold/Flu Resistance | Self-Reported Change based on a 7 point range from Much Better (+3) to Much Worse (-3) | From baseline through study completion, an average of 15 weeks |
| Stress Tolerance | Self-Reported Change based on a 7 point range from Much Better (+3) to Much Worse (-3) | From baseline through study completion, an average of 15 weeks |
| Energy Level | Self-Reported Change based on a 7 point range from Much Better (+3) to Much Worse (-3) | From baseline through study completion, an average of 15 weeks |
| Endurance | Self-Reported Change based on a 7 point range from Much Better (+3) to Much Worse (-3) | From baseline through study completion, an average of 15 weeks |
| Ease of Walking | Self-Reported Change based on a 7 point range from Much Better (+3) to Much Worse (-3) | From baseline through study completion, an average of 15 weeks |
| Climbing Stairs | Self-Reported Change based on a 7 point range from Much Better (+3) to Much Worse (-3) | From baseline through study completion, an average of 15 weeks |
| Overall Mood | Self-Reported Change based on a 7 point range from Much Better (+3) to Much Worse (-3) | From baseline through study completion, an average of 15 weeks |
| Vitality | Self-Reported Change based on a 7 point range from Much Better (+3) to Much Worse (-3) | From baseline through study completion, an average of 15 weeks |
| 9315443 | Background | Villeponteau B. The heterochromatin loss model of aging. Exp Gerontol. 1997 Jul-Oct;32(4-5):383-94. doi: 10.1016/s0531-5565(96)00155-6. |
| 9343401 | Background | Marusic L, Anton M, Tidy A, Wang P, Villeponteau B, Bacchetti S. Reprogramming of telomerase by expression of mutant telomerase RNA template in human cells leads to altered telomeres that correlate with reduced cell viability. Mol Cell Biol. 1997 Nov;17(11):6394-401. doi: 10.1128/MCB.17.11.6394. |
| 7613096 | Background | Harley CB, Villeponteau B. Telomeres and telomerase in aging and cancer. Curr Opin Genet Dev. 1995 Apr;5(2):249-55. doi: 10.1016/0959-437x(95)80016-6. |
| D007154 | Immune System Diseases |